[{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IBD0333","moa":"4-1BB \/ CD24","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"BMND08","moa":"5-HT2A receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","highestDevelopmentStatusID":"7","companyTruncated":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo"},{"orgOrder":0,"company":"Clinical Testing of Beverly Hills","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Clinical Testing of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinical Testing of Beverly Hills \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Clinical Testing of Beverly Hills \/ Galderma"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"AdvanCell","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Acadesine","moa":"AMP-activated protein kinase, AMPK","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ AdvanCell","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ AdvanCell"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MV130","moa":"Bacterial antigens","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Beta-lactam antibiotics","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ONO-5334","moa":"Cathepsin K","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AT-1501","moa":"CD40 ligand","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eledon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HYP-2090PTSA","moa":"Class 1 PI3K\/KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Viscogel AB","sponsor":"Karolinska Institutet | Pharma Consulting Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Viscogel AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viscogel AB \/ Karolinska Institutet | Pharma Consulting Group","highestDevelopmentStatusID":"7","companyTruncated":"Viscogel AB \/ Karolinska Institutet | Pharma Consulting Group"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Mayo Clinic \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Mayo Clinic \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TURKEY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Diclofenac Potassium","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Orinove","sponsor":"Fosun Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ORIN1001","moa":"Endoplasmic reticulum to nucleus signaling 1 (ERN1)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Orinove","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orinove \/ Fosun Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Orinove \/ Fosun Pharma"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lazertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lazertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Globe Biotech Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BANGLADESH","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Erythropoietin Alfa","moa":"EPO receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Globe Biotech Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Globe Biotech Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Globe Biotech Limited \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"MAP Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"MAP0004","moa":"ergot alkaloid derivatives","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allergan \/ MAP Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Allergan \/ MAP Pharmaceuticals"},{"orgOrder":0,"company":"Allergan","sponsor":"MAP Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"MAP0004","moa":"ergot alkaloid derivatives","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allergan \/ MAP Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Allergan \/ MAP Pharmaceuticals"},{"orgOrder":0,"company":"Allergan","sponsor":"MAP Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"MAP0004","moa":"ergot alkaloid derivatives","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ MAP Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Allergan \/ MAP Pharmaceuticals"},{"orgOrder":0,"company":"Allergan","sponsor":"MAP Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"MAP0004","moa":"ergot alkaloid derivatives","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ MAP Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Allergan \/ MAP Pharmaceuticals"},{"orgOrder":0,"company":"PureTech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LYT-300","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"PureTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"PureTech \/ Novotech"},{"orgOrder":0,"company":"Coeruleus Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Flumazenil","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Coeruleus Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Coeruleus Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Coeruleus Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Allaysis","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Allaysis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allaysis \/ University of Minnesota","highestDevelopmentStatusID":"7","companyTruncated":"Allaysis \/ University of Minnesota"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"DLBS2411","moa":"Gastric acid secretion","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"NR3C1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"Glutamate [NMDA] receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"VistaGen Therapeutics \/ Parexel"},{"orgOrder":0,"company":"Temple Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L Alanyl L Glutamine Excipient","moa":"Glutamine receptor (GluR)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Temple Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Temple Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Temple Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Targovax","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"ONCOS-102","moa":"GM-CSF","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Theradex"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hepenofovir Fumarate","moa":"HBV DNA polymerase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"INX-08189","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"INX-08189","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"INX-08189","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"National Institute of Allergy and Infectious Diseases | US Military HIV Research Program | Beth Israel Deaconess Medical Center | IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ad26.Mos.HIV","moa":"HIV-1 antigen","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ National Institute of Allergy and Infectious Diseases | US Military HIV Research Program | Beth Israel Deaconess Medical Center | IAVI","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ National Institute of Allergy and Infectious Diseases | US Military HIV Research Program | Beth Israel Deaconess Medical Center | IAVI"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ad26.Mos.HIV","moa":"HIV-1 antigen","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ad26.Mos.HIV","moa":"HIV-1 antigen","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"McGill University","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Lallemand Health Solutions","highestDevelopmentStatusID":"7","companyTruncated":"McGill University \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Physician Reference Laboratory | Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ioforminol","moa":"iodine-containing contrast media","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GE Healthcare \/ Physician Reference Laboratory | Quintiles Inc","highestDevelopmentStatusID":"7","companyTruncated":"GE Healthcare \/ Physician Reference Laboratory | Quintiles Inc"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dexrazoxane","moa":"Iron | DNA topoisomerase II","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"D3S-001","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Undisclosed"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"D3S-001","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"D3 Bio \/ Fortrea","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Fortrea"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV8.hLCA5","moa":"LCA5","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ University of Pennsylvania"},{"orgOrder":0,"company":"Dr. Emma's Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Human Chorionic Gonadotropin","moa":"Luteinizing hormone\/Choriogonadotropin receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Dr. Emma's Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Emma's Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dr. Emma's Corporation \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zampilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Zampilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Frontier Biotechnologies | Shanghai Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FB2001","moa":"Mpro","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ruijin Hospital \/ Frontier Biotechnologies | Shanghai Center for Disease Control and Prevention","highestDevelopmentStatusID":"7","companyTruncated":"Ruijin Hospital \/ Frontier Biotechnologies | Shanghai Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Vanda Pharmaceuticals \/ Mayo Clinic"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Cross Research S.A.","highestDevelopmentStatusID":"7","companyTruncated":"Vanda Pharmaceuticals \/ Cross Research S.A."},{"orgOrder":0,"company":"Contract Research Organization el AB","sponsor":"Swedish Match AB","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Contract Research Organization el AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pouch","sponsorNew":"Contract Research Organization el AB \/ Swedish Match AB","highestDevelopmentStatusID":"7","companyTruncated":"Contract Research Organization el AB \/ Swedish Match AB"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Peking Union Medical College Hospital \/ Merck Group"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ADX-629","moa":"RASP","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"MAXVAX Biotechnology","sponsor":"Henan Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Respiratory Syncytial Virus Vaccine","moa":"RSV","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"MAXVAX Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAXVAX Biotechnology \/ Henan Center for Disease Control and Prevention","highestDevelopmentStatusID":"7","companyTruncated":"MAXVAX Biotechnology \/ Henan Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine","moa":"RSV","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"GeneOne Life Science, Inc","sponsor":"Inovio Pharmaceuticals | International Vaccine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"GLS-5300","moa":"SARS-CoV-2 S","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"GeneOne Life Science, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneOne Life Science, Inc \/ Inovio Pharmaceuticals | International Vaccine Institute","highestDevelopmentStatusID":"7","companyTruncated":"GeneOne Life Science, Inc \/ Inovio Pharmaceuticals | International Vaccine Institute"},{"orgOrder":0,"company":"GeneOne Life Science, Inc","sponsor":"Inovio Pharmaceuticals | Walter Reed Army Institute of Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"GLS-5300","moa":"SARS-CoV-2 S","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"GeneOne Life Science, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneOne Life Science, Inc \/ Inovio Pharmaceuticals | Walter Reed Army Institute of Research","highestDevelopmentStatusID":"7","companyTruncated":"GeneOne Life Science, Inc \/ Inovio Pharmaceuticals | Walter Reed Army Institute of Research"},{"orgOrder":0,"company":"EYEGENE","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EG-COVID-003","moa":"SARS-CoV-2 spike protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"EYEGENE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"EYEGENE \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"EYEGENE \/ Novotech"},{"orgOrder":0,"company":"Empower Research","sponsor":"Empower Psychedelics | Centre for Neurology Studies | Mitacs","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Empower Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Empower Research \/ Empower Psychedelics | Centre for Neurology Studies | Mitacs","highestDevelopmentStatusID":"7","companyTruncated":"Empower Research \/ Empower Psychedelics | Centre for Neurology Studies | Mitacs"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"ARYx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ ARYx Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Mayo Clinic \/ ARYx Therapeutics"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Bristol Myers Squibb | Clinical Trials in Organ Transplantation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Lulizumab Pegol","moa":"T-cell-specific surface glycoprotein CD28","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Bristol Myers Squibb | Clinical Trials in Organ Transplantation","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Bristol Myers Squibb | Clinical Trials in Organ Transplantation"},{"orgOrder":0,"company":"Genexine","sponsor":"SYMYOO Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"GX-30","moa":"Thyroid stimulating hormone receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genexine \/ SYMYOO Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ SYMYOO Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Centre Antoine Lacassagne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Centre Antoine Lacassagne","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Antoine Lacassagne \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Centre Antoine Lacassagne \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glumetinib","moa":"tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Glumetinib","moa":"tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Glumetinib","moa":"tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"JSP191","moa":"Tyrosine-protein kinase Kit (KIT)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CHA Vaccine Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CVI-HBV-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"CHA Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHA Vaccine Institute \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CHA Vaccine Institute \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Immunophage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IPG7236","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Nanjing Immunophage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Immunophage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanjing Immunophage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Rhthrombin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UMN Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ASP7374","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"UMN Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMN Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UMN Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"A\/H5N1 Antigen","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Cultured Keratinocytes","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organogenesis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Organogenesis \/ Undisclosed"},{"orgOrder":0,"company":"BonusBio Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Autologous Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"BonusBio Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BonusBio Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BonusBio Group \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Affini-T Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Affini-T Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Affini-T Therapeutics"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"AV0328","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alopexx Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alopexx Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Queensland Institute of Medical Research | Q-Pharm Pty Limited | Trident Clinical Research Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Blood Stage Parasite Inoculum","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines for Malaria Venture \/ Queensland Institute of Medical Research | Q-Pharm Pty Limited | Trident Clinical Research Pty Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Medicines for Malaria Venture \/ Queensland Institute of Medical Research | Q-Pharm Pty Limited | Trident Clinical Research Pty Ltd"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CHI-560","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Canopy Growth Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Citric Acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Prothya Biosolutions","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Cofact","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Prothya Biosolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothya Biosolutions \/ PRA Health Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Prothya Biosolutions \/ PRA Health Sciences"},{"orgOrder":0,"company":"CeNeRx BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Cxb","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"CeNeRx BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CeNeRx BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CeNeRx BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"National Cancer Institute | Revimmune","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CYT107","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ National Cancer Institute | Revimmune","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ National Cancer Institute | Revimmune"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Clinical Trials in Organ Transplantation in Children | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Dartregs","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation in Children | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation in Children | Rho, Inc"},{"orgOrder":0,"company":"ExeGi","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ The Emmes Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rambam Health Care Campus \/ Tel Aviv Sourasky Medical Center (Ichilov Hospital)","highestDevelopmentStatusID":"7","companyTruncated":"Rambam Health Care Campus \/ Tel Aviv Sourasky Medical Center (Ichilov Hospital)"},{"orgOrder":0,"company":"Igy Nutrition, LLC","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Immunoglobulin Y","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Igy Nutrition, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Igy Nutrition, LLC \/ Nutrasource","highestDevelopmentStatusID":"7","companyTruncated":"Igy Nutrition, LLC \/ Nutrasource"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ION440","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Statens Serum Institut","sponsor":"Bill & Melinda Gates Foundation | CCBR Clinical Research | Larix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"IPV-Al SSI","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Statens Serum Institut","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Statens Serum Institut \/ Bill & Melinda Gates Foundation | CCBR Clinical Research | Larix","highestDevelopmentStatusID":"7","companyTruncated":"Statens Serum Institut \/ Bill & Melinda Gates Foundation | CCBR Clinical Research | Larix"},{"orgOrder":0,"company":"Second Affiliated Hospital, Guangzhou Medical University","sponsor":"Hunan Zhaotai Yongren Medical Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ITNK cell therapy","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Second Affiliated Hospital, Guangzhou Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Second Affiliated Hospital, Guangzhou Medical University \/ Hunan Zhaotai Yongren Medical Innovation","highestDevelopmentStatusID":"7","companyTruncated":"Second Affiliated Hospital, Guangzhou Medical University \/ Hunan Zhaotai Yongren Medical Innovation"},{"orgOrder":0,"company":"Juntendo University","sponsor":"Junten Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"JB-101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Juntendo University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juntendo University \/ Junten Bio","highestDevelopmentStatusID":"7","companyTruncated":"Juntendo University \/ Junten Bio"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"JNJ-64213175","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Good Food Practice, Sweden","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"L. reuteri DSM 17938","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Good Food Practice, Sweden","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Good Food Practice, Sweden \/ BioGaia Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Good Food Practice, Sweden \/ BioGaia Pharma"},{"orgOrder":0,"company":"Xenothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LIS1","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Xenothera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenothera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xenothera \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"MDG1011","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chenland Nutritionals","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Moodelite T-4003-1","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Chenland Nutritionals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chenland Nutritionals \/ KGK Science","highestDevelopmentStatusID":"7","companyTruncated":"Chenland Nutritionals \/ KGK Science"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Shanghai AbelZeta Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MPCs-derived exosomes","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ruijin Hospital \/ Shanghai AbelZeta Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Ruijin Hospital \/ Shanghai AbelZeta Ltd."},{"orgOrder":0,"company":"Songqi Gao","sponsor":"Gabrail Cancer Center Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MT218","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Songqi Gao","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Songqi Gao \/ Gabrail Cancer Center Research","highestDevelopmentStatusID":"7","companyTruncated":"Songqi Gao \/ Gabrail Cancer Center Research"},{"orgOrder":0,"company":"Clinical Research Center Kiel GmbH","sponsor":"European Commission | Food & Biobased Research - Wageningen UR | Teagasc | Nofima | BioActor | Swedish Oat Fiber AB | Immitec | Institut Pasteur | University of Bologna","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Non-Digestible Polysaccharides","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Clinical Research Center Kiel GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Research Center Kiel GmbH \/ European Commission | Food & Biobased Research - Wageningen UR | Teagasc | Nofima | BioActor | Swedish Oat Fiber AB | Immitec | Institut Pasteur | University of Bologna","highestDevelopmentStatusID":"7","companyTruncated":"Clinical Research Center Kiel GmbH \/ European Commission | Food & Biobased Research - Wageningen UR | Teagasc | Nofima | BioActor | Swedish Oat Fiber AB | Immitec | Institut Pasteur | University of Bologna"},{"orgOrder":0,"company":"Nuseed Americas Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Nutriterra","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Nuseed Americas Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuseed Americas Inc. \/ Nutrasource","highestDevelopmentStatusID":"7","companyTruncated":"Nuseed Americas Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Rion","sponsor":"Henry M. Jackson Foundation | Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Pep Purified Exosome Product","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ Henry M. Jackson Foundation | Walter Reed National Military Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Rion \/ Henry M. Jackson Foundation | Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pneumococcal 26-valent Conjugate Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RNK08954-01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ranok Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Soluble Viscous Fibre Blend Powder in Hydrophobic Matrix","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"PATH","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Trivalent P2-VP8 Subunit Rotavirus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PATH \/ The Emmes Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"PATH \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Meribank Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Meribank Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meribank Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Meribank Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Intralytix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Vrelysin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Intralytix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Intralytix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intralytix \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Puhe Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"YK-029A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Suzhou Puhe Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Puhe Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Suzhou Puhe Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HY07121","moa":"Unknown","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SINTETICA SA \/ Cross Research S.A.","highestDevelopmentStatusID":"7","companyTruncated":"SINTETICA SA \/ Cross Research S.A."},{"orgOrder":0,"company":"University of Colorado, Boulder","sponsor":"TheraVasc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Boulder","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Boulder \/ TheraVasc","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Boulder \/ TheraVasc"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Altesa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Changchun BCHT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Changchun BCHT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changchun BCHT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Changchun BCHT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vanarix SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vanarix SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vanarix SA \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vanarix SA \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Best Buy Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brigham and Women's Hospital \/ Best Buy Health","highestDevelopmentStatusID":"7","companyTruncated":"Brigham and Women's Hospital \/ Best Buy Health"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Framingham Heart Study | Jackson Heart Study | Broad Institute of MIT and Harvard | University of Mississippi Medical Center | Boston University | Partners HealthCare","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brigham and Women's Hospital \/ Framingham Heart Study | Jackson Heart Study | Broad Institute of MIT and Harvard | University of Mississippi Medical Center | Boston University | Partners HealthCare","highestDevelopmentStatusID":"7","companyTruncated":"Brigham and Women's Hospital \/ Framingham Heart Study | Jackson Heart Study | Broad Institute of MIT and Harvard | University of Mississippi Medical Center | Boston University | Partners HealthCare"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Marijn Lijffijt, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"Glutamate [NMDA] receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Marijn Lijffijt, PhD","highestDevelopmentStatusID":"7","companyTruncated":"VistaGen Therapeutics \/ Marijn Lijffijt, PhD"},{"orgOrder":0,"company":"Dong-A Pharmaceutical","sponsor":"Myung-gui Choi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"DA-9701","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Dong-A Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A Pharmaceutical \/ Myung-gui Choi","highestDevelopmentStatusID":"7","companyTruncated":"Dong-A Pharmaceutical \/ Myung-gui Choi"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Respiratory Syncytial Virus Vaccine

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Respiratory Syncytial Virus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 07, 2022

                          Lead Product(s) : Respiratory Syncytial Virus Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Plerixafor

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : E. Steve Woodle

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Plerixafor is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 13, 2015

                          Lead Product(s) : Plerixafor

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : E. Steve Woodle

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Lead Product(s) : Plerixafor

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Mitchell Horwitz, MD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Plerixafor is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 21, 2011

                          Lead Product(s) : Plerixafor

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Mitchell Horwitz, MD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          04

                          Vanarix SA

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Vanarix SA

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 26, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 19, 2025

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : BMND08

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : BMND08 is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : BMND08

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Pep Purified Exosome Product

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I/ Phase II

                          Sponsor : Henry M. Jackson Foundation | Walter Reed National Military Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Pep Purified Exosome Product is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : Pep Purified Exosome Product

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Henry M. Jackson Foundation | Walter Reed National Military Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : CM313 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          January 24, 2025

                          Lead Product(s) : CM313

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Beijing Zhifei Lvzhu Biopharmaceutical

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Beijing Zhifei Lvzhu Biopharmaceutical

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Pneumococcal 26-valent Conjugate Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 25, 2024

                          Lead Product(s) : Pneumococcal 26-valent Conjugate Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : ASC30 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 08, 2024

                          Lead Product(s) : ASC30

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank